Biomerica (NASDAQ:BMRA) Director David Moatazedi Purchases 10,000 Shares of Stock

Biomerica, Inc. (NASDAQ:BMRA) Director David Moatazedi bought 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were bought at an average price of $1.60 per share, for a total transaction of $16,000.00. Following the acquisition, the director directly owned 40,625 shares of the company’s stock, valued at $65,000. This represents a 32.65% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Biomerica Price Performance

NASDAQ BMRA traded up $0.41 on Thursday, hitting $2.10. 3,239,684 shares of the stock were exchanged, compared to its average volume of 36,798. The company has a market capitalization of $6.49 million, a PE ratio of -2.36 and a beta of 0.35. The business’s fifty day moving average is $1.65 and its 200 day moving average is $1.99. Biomerica, Inc. has a 52 week low of $1.45 and a 52 week high of $3.24.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Weiss Ratings lowered Biomerica from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, June 5th. Citizens Jmp began coverage on Biomerica in a report on Tuesday, May 5th. They set a “mkt outperform” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell” and a consensus price target of $9.00.

Institutional Investors Weigh In On Biomerica

An institutional investor recently raised its stake in Biomerica stock. DRW Securities LLC increased its position in Biomerica, Inc. (NASDAQ:BMRA) by 62.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,925 shares of the company’s stock after buying an additional 6,533 shares during the quarter. DRW Securities LLC owned 0.56% of Biomerica worth $43,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 22.28% of the stock is owned by hedge funds and other institutional investors.

About Biomerica

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.